Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2017
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma
Kevin D Courtney, Jeffrey R Infante, Elaine T Lam, et al.
Targeted Oncology
|
April 3, 2025
Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial
Jose De La Cerda, Laurence Belkoff, Kevin D Courtney, et al.
Clinical Genitourinary Cancer
|
December 3, 2014
A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer
Kevin D Courtney, Judith B Manola, Aymen A Elfiky, et al.
Cell Metabolism
|
August 28, 2018
Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo
Kevin D Courtney, Divya Bezwada, Tomoyuki Mashimo, et al.
Advances in Radiation Oncology
|
September 22, 2025
Extracranial Palliative Radiation Therapy for Renal Cell Carcinoma
Young Suk Kwon, Eric Hsu, Maggie Stein, et al.
Nature Chemical Biology
|
October 25, 2019
Author Correction: MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG
Louise Fets, Paul C Driscoll, Fiona Grimm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2025
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
Sumanta K Pal, Yohann Loriot, Andrea Necchi, et al.
Nature Chemical Biology
|
October 10, 2018
MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG
Louise Fets, Paul C Driscoll, Fiona Grimm, et al.
Frontiers in Oncology
|
January 22, 2025
Initial clinical experience with [<sup>177</sup>Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial
Aaron R Hansen, Stephan Probst, Jean-Mathieu Beauregard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2019
HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
Kevin D Courtney, Yuanqing Ma, Alberto Diaz de Leon, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2017
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma
Kevin D Courtney, Jeffrey R Infante, Elaine T Lam, et al.
Targeted Oncology
|
April 3, 2025
Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial
Jose De La Cerda, Laurence Belkoff, Kevin D Courtney, et al.
Clinical Genitourinary Cancer
|
December 3, 2014
A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer
Kevin D Courtney, Judith B Manola, Aymen A Elfiky, et al.
Cell Metabolism
|
August 28, 2018
Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo
Kevin D Courtney, Divya Bezwada, Tomoyuki Mashimo, et al.
Advances in Radiation Oncology
|
September 22, 2025
Extracranial Palliative Radiation Therapy for Renal Cell Carcinoma
Young Suk Kwon, Eric Hsu, Maggie Stein, et al.
Nature Chemical Biology
|
October 25, 2019
Author Correction: MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG
Louise Fets, Paul C Driscoll, Fiona Grimm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2025
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
Sumanta K Pal, Yohann Loriot, Andrea Necchi, et al.
Nature Chemical Biology
|
October 10, 2018
MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG
Louise Fets, Paul C Driscoll, Fiona Grimm, et al.
Frontiers in Oncology
|
January 22, 2025
Initial clinical experience with [<sup>177</sup>Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial
Aaron R Hansen, Stephan Probst, Jean-Mathieu Beauregard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2019
HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
Kevin D Courtney, Yuanqing Ma, Alberto Diaz de Leon, et al.
Page
of 3